Content about Hematology

June 1, 2011
XTL granted orphan drug designation for multiple myeloma treatment

The Food and Drug Administration has given orphan drug designation to an investigational treatment for multiple myeloma, a blood cell cancer, that soon will enter mid-stage development.

May 23, 2011
Pump up the iron


It’s not often a niche brand manufacturer attempts to resuscitate what has been for years a commoditized category. But that’s exactly what Meda Consumer Healthcare will be attempting to do with iron — establish a good/better/best proposition to a supplemented category best defined as mediocre.

April 1, 2011
Watson receives FDA approval for Nulecit

The Food and Drug Administration has approved a generic treatment for iron deficiency anemia made by Watson Pharmaceuticals, Watson said Thursday.

February 24, 2011
Novo Nordisk develops treatment for rarest bleeding disorder, seeks FDA approval

Novo Nordisk has filed for approval of a treatment for a rare genetic bleeding disorder, the Danish drug maker said Wednesday.

February 18, 2011
FDA OKs Corifact

The Food and Drug Administration has approved a treatment for a rare bleeding disorder.

December 9, 2010
Study shows 50% reduction of myeloma among patients

A new three-drug combination may work as a front-line treatment for cancer of the plasma cells, according to an early-stage clinical study.

December 7, 2010
Watson, Natco ink deal for generic Revlimid

U.S. generic drug maker Watson Pharmaceuticals and Indian drug maker Natco Pharma will work together to develop and commercialize a generic drug used for bone marrow disorders, the two companies said Tuesday.

December 6, 2010
Amgen: Nplate may help patients with autoimmune bleeding disorder

A drug made by Amgen maintained blood platelet counts in patients with an autoimmune bleeding disorder, according to results of a five-year study released Sunday.

December 6, 2010
Genentech: Rituxan improved asymptomatic follicular lymphoma symptoms among patients in trial

A biotech drug made by Roche subsidiary Genentech allowed patients with a blood cancer, who did not show symptoms, to delay starting on chemotherapy or radiotherapy, and decreased the risk of their disease worsening, according to results of a late-stage clinical trial.

August 2, 2010
Octapharma gets orphan drug status for Wilate

The Food and Drug Administration has given orphan drug designation to a treatment for an...

June 29, 2010
Eisai, SuperGen release data for Dacogen trial

Japanese drug maker Eisai has released data on a late-stage clinical trial of a drug...

June 29, 2010
Sanofi-Aventis to acquire TargeGen

A biotechnology company will be acquired by one of the world's largest drug makers....

May 12, 2010
Octapharma launches bleeding disorder treatment

A drug for treating the bleeding disorder von Willebrand disease has become available, manufacturer Octapharma...

March 29, 2010
Pliva Hrvastka gets tentative approval for argatroban

The Food and Drug Administration has given a tentative approval to a generic drug for...

March 7, 2010
Clinical study: Pfizer-Bristol anticoagulant more effective than competitior

A pill-based anticoagulant drug under development by Pfizer and Bristol-Myers Squibb worked better in reducing...

January 17, 2010
MedPro Rx offering scholarships to students with bleeding disorders

Prospective college students living with bleeding disorders have a chance to receive a scholarship from...

© 2013 Drug Store News. All Rights Reserved.